Professor Cliff Bailey and Dr Martin Hadley-Brown provide a 30 minute update on what you need to know about SGLT2 inhibitors from the 2021 congresses.
Long Covid: Broadcast 3
‘On-demand’ sessions from Broadcast 3 of the 2021 Primary Care Issues & Answers Live Inaugural Broadcasts – Long Covid: The way ahead. Includes supporting slide sets and factsheets.
Long Covid: Broadcast 2
‘On-demand’ sessions from Broadcast 2 of the 2021 Primary Care Issues & Answers Live Inaugural Broadcasts – Long Covid: The way ahead. Includes supporting slide sets and factsheets.
Long Covid: Broadcast 1
‘On-demand’ sessions from Broadcast 1 of the 2021 Primary Care Issues & Answers Live Inaugural Broadcasts – Long Covid: The way ahead. Includes supporting slide sets and factsheets.
ABC of CVD: What primary care need to know
Beverley Bostock takes us through the ABC of cardiovascular disease – Atrial fibrillation, blood pressure and cholesterol.
GLP-1 (3/3): Translating theory into practice. An interactive case-based discussion
Su Down and Dr Kevin Fernando translate the theory into practice with case based discussion covering glucose management and initiating GLP-1 RA for CV benefit.
Heart Failure – The new standard of care
Dr Yassir Javaid discusses the modern management of heart failure from a cardiovascular perspective.
GLP-1 (2/3): Practicalities of starting GLP-1 receptor agonist therapy
Jane Diggle and Nicola Milne discuss GLP-1 Receptor Agonists so you can enhance your knowledge and gain confidence in the practicalities of initiating GLP-1 receptor agonists effectively in daily practice.
GLP-1 (1/3): Understanding the incretin effect and GLP-1 receptor agonist therapy
Jane Diggle and her expert colleagues will discuss GLP-1 Receptor Agonists including ‘Understanding the Incretin effect and GLP-1 Receptor Agonist Therapy’ by Professor Michael Cummings.
SGLT2 (3/5) – SGLT2 inhibitors and the kidney
Professor Cliff Bailey and Dr Pam Brown discuss the Reno-protective effects of SGLT2 inhibitors and the role of SGLT2 inhibitors in the management of diabetic kidney disease.
SGLT2 (2/5) – SGLT2 inhibitors and the heart
Professor Cliff Bailey and Dr Martin Hadley-Brown discuss the effects of SGLT2 inhibitors on cardiovascular function and the role of SGLT2 inhibitors in the management of CV disease.
SGLT2 (1/5) – Understanding SGLT2 inhibition
Professor Cliff Bailey and Professor Vinod Patel assess the clinical evidence and opportunities offered by sodium-glucose co-transporter-2 (SGLT2) inhibitors in the management of type 2 diabetes and its cardio-renal complications.